- Hologic Inc HOLX has obtained a CE Mark to use saliva samples with its Aptima SARS-CoV-2 assay in Europe.
- The Aptima SARS-CoV-2 test is a molecular diagnostic assay that detects the pathogen's genetic material causing COVID-19.
- The test runs on the fully automated Panther system.
- Hologic has expanded its manufacturing capability to produce Aptima tests in large quantities and has shipped more than 100 million Aptima COVID-19 tests globally since the spring of 2020.
- Approximately 2,600 Panther systems have been installed in clinical diagnostic laboratories around the world.
- Price Action: HOLX shares closed at $68.65 on Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
